Medical Oncology

, Volume 29, Issue 3, pp 1707–1710 | Cite as

Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma

  • Ulas Darda Bayraktar
  • Soley Bayraktar
  • Peter Hosein
  • Emerson Chen
  • Leonidas G. Koniaris
  • Caio Max S. Rocha-Lima
  • Alberto J. Montero
Short Communication

Abstract

Perioperative chemotherapy plus surgery improves survival compared to surgery alone in GE junctional (GEJ) and gastric adenocarcinomas. The docetaxel/cisplatin/5-fluorouracil (DCF) combination is superior to CF in patients with metastatic gastric cancer. We retrospectively evaluated the safety and efficacy of preoperative DCF chemotherapy in patients with locally advanced gastric and GEJ cancer. Twenty-one gastric and 10 gastroesophageal junctional (GEJ) cancer patients received 2–3 cycles of preoperative docetaxel 75 mg/m2 and cisplatin 75 mg/m2 on day 1, 5-FU 750 mg/m2 (continuous infusion) on days 1–5 every 3 weeks. Clinical response was evaluated by comparing pre- and postchemotherapy CT scans. Overall survival (OS) and progression-free survival (PFS) were calculated from the initiation of chemotherapy. None of the patients achieved complete clinical remission while 11 (35%) patients achieved partial clinical remission. Ten patients with GEJ cancer (100%) and 13 with gastric cancer (62%) underwent curative surgery (P = 0.023). Seventeen (55%) patients experienced grade 3–4 chemotherapy-related adverse events. The most common adverse events were anemia, nausea/vomiting, diarrhea, and febrile neutropenia. At a median follow-up of 17.0 months, median OS and PFS were 26.1 months (95% CI: 22.7–29.5) and 18.8 months (95% CI: 9.9–27.7), respectively. The DCF regimen is active in patients with gastric and GEJ adenocarcinoma in the preoperative setting.

Keywords

Gastric cancer Esophageal cancer Preoperative chemotherapy Docetaxel 

Notes

Conflict of interest

Authors declare no conflicts of interest or pertinent financial relationships.

References

  1. 1.
    Schuhmacher CP, Fink U, Becker K, Busch R, Dittler HJ, Mueller J, et al. Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxorubicin, and cisplatinum. Cancer. 2001;91:918–27.PubMedCrossRefGoogle Scholar
  2. 2.
    Ott K, Sendler A, Becker K, Dittler HJ, Helmberger H, Busch R, et al. Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer. Gastric Cancer. 2003;6:159–67.PubMedCrossRefGoogle Scholar
  3. 3.
    Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJH, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–21.PubMedCrossRefGoogle Scholar
  4. 4.
    Einzig AI, Neuberg D, Remick SC, Karp DD, O’Dwyer PJ, Stewart JA, et al. Phase II trial of docetaxel in patients with adenocarcinoma of the upper gastrointestinal tract. Med Oncol. 1996;13:1263–6.Google Scholar
  5. 5.
    Sulkes A, Smyth J, Sessa C, Dirix LY, Vermorken JB, Kaye S, et al. Docetaxel in advanced gastric cancer: results of a phase II clinical trial. Br J Cancer. 1994;70:380–3.PubMedCrossRefGoogle Scholar
  6. 6.
    Roth AD, Maibach R, Martinelli G, Fazio N, Aapro MS, Pagani O, et al. Docetaxel-cisplatin (TC): an effective drug combination in gastric carcinoma. Ann Oncol. 2000;11:301–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Constenla M, Garcia-Arroyo R, Lorenzo I, Carrete N, Campos B, Palacios P. Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study. Gastric Cancer. 2002;5:142–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III Study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer. J Clin Oncol. 2006;24:4991–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Roth DA, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, et al. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2007;25:3217–23.PubMedCrossRefGoogle Scholar
  10. 10.
    Ajani JA, Van Cutsem E, Moiseyenko V, Tjulandin S, Fodor M, Majlis A, et al. Docetaxel (D), cisplatin, 5-fluorouracil compare to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naïve patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): Interim results of a randomized phase III trial (V325). 2003 (ASCO Annual Meeting, abstract 999).Google Scholar
  11. 11.
    Ma Y, Qin H, Zheng Q, Wang Y, Wang Z, Yang Z. Neoadjuvant chemotherapy with a combination of docetaxel, cisplatin, fluorouracil, and leucovorin in nonresectable advanced gastric cancer. Med Oncol. 2010;27(4):1089–95.PubMedCrossRefGoogle Scholar
  12. 12.
    Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Filho SC, et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol. 2005;23:5660–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Helmberger H, Baum U, Dittler HJ, Sendler A, Schulte B, Herter B, et al. Adenocarcinoma of the gastro-esophageal junction: CT for monitoring during neoadjuvant chemotherapy. Eur J Radiol. 1996;23:107–10.PubMedCrossRefGoogle Scholar
  14. 14.
    Guo MG, Zheng Q, Cheng Z, Wang Y, Feng CN, Yang Z. The combination of docetaxel and cisplatin plus fluorouracil as neoadjuvant chemotherapy in the treatment of T4 stage gastric cancer. Surg Oncol. 2010;19(1):1–3.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Ulas Darda Bayraktar
    • 1
  • Soley Bayraktar
    • 1
  • Peter Hosein
    • 1
  • Emerson Chen
    • 2
  • Leonidas G. Koniaris
    • 3
  • Caio Max S. Rocha-Lima
    • 1
  • Alberto J. Montero
    • 1
  1. 1.Division of Hematology/Oncology, Department of Medicine, Sylvester Comprehensive Cancer CenterUniversity of MiamiMiamiUSA
  2. 2.University of Miami Miller School of MedicineMiamiUSA
  3. 3.Division of Surgical Oncology, Department of Surgery, Sylvester Comprehensive Cancer CenterUniversity of MiamiMiamiUSA

Personalised recommendations